SEC Comment Letter 0000000000-24-006769 to Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc.
Date: June 13, 2024 · CIK: 0001659617 · Accession: 0000000000-24-006769
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280064
Letter
United States securities and exchange commission logo June 12, 2024 Walter V. Klemp Chief Executive Officer Moleculin Biotech, Inc. 5300 Memorial Drive, Suite 950 Houston, TX 77007 Re:Moleculin Biotech, Inc. Registration Statement on Form S-3 Filed June 7, 2024 File No. 333-280064 Dear Walter V. Klemp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cavas S. Pavri
Show Raw Text
United States securities and exchange commission logo
June 12, 2024
Walter V. Klemp
Chief Executive Officer
Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, TX 77007
Re:Moleculin Biotech, Inc.
Registration Statement on Form S-3
Filed June 7, 2024
File No. 333-280064
Dear Walter V. Klemp:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Cavas S. Pavri